Search Result

Results for "

abnormal kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Aurora Kinase (4) Autophagy (3) Bcr-Abl (3) Biochemical Assay Reagents (1) c-Kit (3) Calmodulin (1) CDK (2) EGFR (1) Endogenous Metabolite (1) ERK (1) FAK (1) FGFR (1) Filovirus (1) G Protein-coupled Receptor Kinase (GRK) (1) IGF-1R (1) MAP3K (1) Myosin (1) p38 MAPK (1) PDGFR (4) Phosphodiesterase (PDE) (1) PI3K (1) Raf (2) Ras (1) Reference Standards (2) RET (1) SphK (1) TAM Receptor (1) VEGFR (1) Wee1 (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (2)

By Targets:

Apoptosis (3)

Aurora Kinase (4)

Autophagy (3)

Bcr-Abl (3)

Biochemical Assay Reagents (1)

c-Kit (3)

Calmodulin (1)

CDK (2)

EGFR (1)

Endogenous Metabolite (1)

ERK (1)

FAK (1)

FGFR (1)

Filovirus (1)

G Protein-coupled Receptor Kinase (GRK) (1)

IGF-1R (1)

MAP3K (1)

Myosin (1)

p38 MAPK (1)

PDGFR (4)

Phosphodiesterase (PDE) (1)

PI3K (1)

Raf (2)

Ras (1)

Reference Standards (2)

RET (1)

SphK (1)

TAM Receptor (1)

VEGFR (1)

Wee1 (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10971

Alisertib Maximum Cited Publications 72 Publications Verification MLN 8237	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-111940

LUT014	Raf p38 MAPK ERK	Inflammation/Immunology
LUT014 is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy .

HY-103032

Multi-kinase inhibitor 1	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent *multi-kinase* inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .

HY-21291

SU-4313	PDGFR EGFR IGF-1R	Cancer
SU-4313 is a potent *protein tyrosine kinases* (PTKs) modulator with IC₅₀*s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase* and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation .

HY-124042

K6PC-5 4 Publications Verification	SphK Filovirus	Infection Neurological Disease Inflammation/Immunology
K6PC-5, a ceramide derivative, is a *sphingosine kinase* 1(SPHK1)** activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research .

HY-161880

WEE1-IN-10	Wee1	Cancer
WEE1-IN-10 (compound 77) is a Wee1 kinase inhibitor. WEE1-IN-10 shows inhibitory activity on LOVO cell growth, with an IC₅₀ of 0.524 μM. WEE1-IN-10 can be used for the research of diseases caused by abnormal activity of Wee1 .

HY-101837

CGP 53716	PDGFR	Inflammation/Immunology
CGP 53716 is a potent protein tyrosine kinase inhibitor. CGP 53716 has selective activity of platelet-derived growth factor (PDGF) receptor. CGP 53716 can be used in the study of disease induced by abnormal cell proliferation induced by PDGF receptor activation .

HY-120997

E6 Berbamine Berbamine p-nitrobenzoate	Calmodulin Myosin Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia .

HY-10971A

Alisertib sodium MLN 8237 sodium	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-152247

DDO3711	MAP3K	Cancer
DDO3711, a PP5-recruiting phosphatase recruitment chimeras (PHORCs), is formed by connecting a small molecular apoptosis signal-regulated kinase 1 (ASK1) inhibitor to a PP5 activator through a chemical linker. DDO3711 specifically inhibits ASK1 (IC₅₀ =164.1 nM) not ASK2 (IC₅₀>20 μM). DDO3711 significantly dephosphorylates p-ASK1 ^T838 by recruiting PP5 and shows the ASK1-dependent antiproliferative activity. DDO3711 has anti-cancer activity and has the potential for abnormally phosphorylated oncoproteins research .

HY-114338B

Dalpiciclib isethionate SHR-6390 isethionate	CDK	Cancer
Dalpiciclib (isethionate) is a CDK4/6 inhibitor. Dalpiciclib (isethionate) inhibits the kinase activity of CDK4 and CDK6, thereby blocking the G1-to-S phase transition of the cell cycle and suppressing abnormal cell proliferation. Dalpiciclib (isethionate) can be used for the study of breast cancer .

HY-148066

DB0662	Biochemical Assay Reagents	Others
DB0662 is a compound for kinase-targeted protein degradation and can be used in studies of diseases mediated by abnormal kinase activity, as well as for the identification of degradable kinases and optimal kinases .

HY-169517

Protein kinase inhibitor 10	TAM Receptor FAK c-Kit	Cancer
Protein kinase inhibitor 10 is a protein kinase inhibitor with IC₅₀ values of 28.9, 13.6, and 2.41 μM for TAM receptor, FAK, and KIT, respectively. Protein kinase inhibitor 10 can inhibit abnormal and excessive cell proliferation, showing promise for research in cancer therapy .

HY-18817

AFG210	Bcr-Abl FGFR Raf RET VEGFR	Cancer
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC₅₀=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase .

HY-10971R

Alisertib (Standard) MLN 8237 (Standard)	Aurora Kinase Autophagy Apoptosis Reference Standards	Cancer
Alisertib (Standard) is the analytical standard of Alisertib. This product is intended for research and analytical applications. Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-W395613

TY-011	Aurora Kinase	Cancer
TY-011 is an Aurora A/B kinase inhibitor. TY-011 induces abnormal microtubule-kinetochore attachment, leading to DNA damage and apoptosis (Apoptosis) in human gastric cancer cells, and ultimately inhibits cancer cell proliferation, with an IC₅₀ value ranging from 0.11 to 4.49 μM in human gastric cancer cell lines. TY-011 has potential applications in gastric cancer research .

HY-E70690

CDK8/CycC Recombinant Human Active Protein Kinase	CDK	Cancer
CDK8 modulates the transcriptional output from distinct transcription factors involved in oncogenic control, including the Wnt/β-catenin pathway, Notch, p53, and transforming growth factor β. Abnormal activity ofCDK8 along with its partner protein cyclin C (CycC) is a common feature of many diseases including colorectal cancer. CDK8/CycC Recombinant Human Active Protein Kinase can be used to study the function of CDK8/CycC .

HY-103032R

Multi-kinase inhibitor 1 (Standard)	Reference Standards PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 (Standard) is the analytical standard of Multi-kinase inhibitor 1 (HY-103032). This product is intended for research and analytical applications. Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .

HY-107387

PF-376304	PI3K	Metabolic Disease Inflammation/Immunology
PF-376304 is an orally active non-specific class I phosphoinositide 3-kinase (PI3K) inhibitor with an IC₅₀ of 0.197 μM against PI3Kγ. PF-376304 induces dose-dependent glucose and lipid metabolic disorders in rats, causes rapid death at high doses, and leads to metabolic abnormalities that are self-reversible at low doses. PF-376304 is applicable to the research of metabolic and inflammatory diseases .

HY-180779

SR-1815	Ras	Neurological Disease
SR-1815 is a small molecule multi-kinase inhibitor. SR-1815, through mechanisms such as splicing regulation effectively restores the SynGAP protein to normal levels in the disease model with Syngap1 haploinsufficiency, thereby correcting the functional abnormalities at the synaptic and neuronal network levels caused by the deficiency of this gene. SR-1815 can be used for the study of brain diseases .

HY-179543

PtdIns-(3,4,5)-P3-(1-stearoyl, 2-arachidonoyl) sodium	Endogenous Metabolite	Others
PtdIns-(3,4,5)-P3-(1-stearoyl, 2-arachidonoyl) sodium is a specific molecular form of phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 is the core lipid messenger in the tyrosine kinase pathway, regulating cell proliferation, survival and metabolism by recruiting effector proteins. Its abnormality is associated with cancer. PtdIns-(3,4,5)-P3-(1-stearoyl, 2-arachidonoyl) sodium can be used for studying lipid signal transduction .

HY-180583

GRK5-IN-5	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GRK5-IN-5 (Compound 4a) is a selective *G protein-coupled receptor (GPCR) kinase* 5 (GRK5) inhibitor with an IC₅₀ of 0.03 μM. GRK5-IN-5 shows IC₅₀** values of 2.2 and 0.036 μM for GRK2 and GRK6. GRK5-IN-5 has potent anti-myocardial hypertrophy activity and also inhibits the proliferation of non-myocardial cells. GRK5-IN-5 can inhibit the abnormal upregulation of hypertrophy marker genes Nppa and Nppb, thus blocking pathological myocardial remodeling. GRK5-IN-5 can be used for the research of cardiac hypertrophy .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library	4,332 compounds
Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR. MCE designs a unique collection of 4,332 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

Protein Kinase Compound Library

4,332 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 4,332 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.